Treatment Patterns and Clinical Outcomes in Patients with Hodgkin Lymphoma from Saudi Arabia, Türkiye, and South Africa: Subgroup Analysis from the International Multicenter Retrospective B-HOLISTIC Study

IF 1.5 4区医学 Q3 HEMATOLOGY Turkish Journal of Hematology Pub Date : 2024-12-02 Epub Date: 2024-10-28 DOI:10.4274/tjh.galenos.2024.2024.0181

David Brittain, Saad Akhtar, Sylvia Rodrigues, Moosa Patel, Dhaya Moodley, Jaimendra Prithipal Singh, Lydia M Dreosti, Zainab Mohamed, Mubarak Al-Mansour, Mohsen Alzahrani, M Shahzad Rauf, Irfan Maghfoor, Sevgi Kalayoğlu Beşışık, Can Boğa, Güray Saydam, Zhongwen Huang, Yacob Pinchevsky, Burhan Ferhanoğlu

{"title":"Treatment Patterns and Clinical Outcomes in Patients with Hodgkin Lymphoma from Saudi Arabia, Türkiye, and South Africa: Subgroup Analysis from the International Multicenter Retrospective B-HOLISTIC Study","authors":"David Brittain, Saad Akhtar, Sylvia Rodrigues, Moosa Patel, Dhaya Moodley, Jaimendra Prithipal Singh, Lydia M Dreosti, Zainab Mohamed, Mubarak Al-Mansour, Mohsen Alzahrani, M Shahzad Rauf, Irfan Maghfoor, Sevgi Kalayoğlu Beşışık, Can Boğa, Güray Saydam, Zhongwen Huang, Yacob Pinchevsky, Burhan Ferhanoğlu","doi":"10.4274/tjh.galenos.2024.2024.0181","DOIUrl":null,"url":null,"abstract":"Objective: B-HOLISTIC was a real-world retrospective study of treatment patterns and clinical outcomes in Hodgkin lymphoma (HL) in regions outside Europe and North America. This subgroup analysis reports findings from Saudi Arabia, Türkiye, and South Africa.Materials and methods: Patients aged ≥18 years and diagnosed with stage IIB-IV classical HL receiving frontline chemotherapy (frontline cHL) and/or with relapsed/refractory HL (RRHL) from January 2010 to December 2013 were assessed. The primary endpoint was progression-free survival (PFS) in patients with RRHL.Results: Overall, 694 patients (RRHL: n=178; frontline cHL: n=653) were enrolled. Among patients with RRHL, >80% received first salvage chemotherapy. The most common first salvage regimens were etoposide, methylprednisolone, cytarabine, and cisplatin in Saudi Arabia (78.3%) and dexamethasone, cytarabine, and cisplatin in Türkiye (36.1%) and South Africa (40%). Median PFS (95% confidence interval [CI]) in the RRHL group was 5.1 (3.0-15.9), 19.7 (7.5-not reached), and 5.2 (1.1-10.1) months in Saudi Arabia, Türkiye, and South Africa, respectively. The 5-year PFS and overall survival (95% CI) rates in patients with RRHL were 33.2% (21.6-45.2) and 78.2% (65.9-86.5) in Saudi Arabia, 42.5% (29.5-54.9) and 79.4% (67.2-87.5) in Türkiye, and 13.1% (4.2-27.0) and 53% (35.5-67.8) in South Africa, respectively.Conclusion: This study showed that the clinical outcomes in Türkiye and Saudi Arabia were generally comparable with those of Western countries during the study period, although Saudi Arabia had lower PFS rates. Conversely, the clinical outcomes in South Africa were suboptimal, emphasizing the need for novel therapies and improved progression to stem cell transplantation. These data may serve as a control group for future studies in these countries and inform clinical decision-making.","PeriodicalId":23362,"journal":{"name":"Turkish Journal of Hematology","volume":" ","pages":"211-224"},"PeriodicalIF":1.5000,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11628755/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish Journal of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4274/tjh.galenos.2024.2024.0181","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/28 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: B-HOLISTIC was a real-world retrospective study of treatment patterns and clinical outcomes in Hodgkin lymphoma (HL) in regions outside Europe and North America. This subgroup analysis reports findings from Saudi Arabia, Türkiye, and South Africa.

Materials and methods: Patients aged ≥18 years and diagnosed with stage IIB-IV classical HL receiving frontline chemotherapy (frontline cHL) and/or with relapsed/refractory HL (RRHL) from January 2010 to December 2013 were assessed. The primary endpoint was progression-free survival (PFS) in patients with RRHL.

Results: Overall, 694 patients (RRHL: n=178; frontline cHL: n=653) were enrolled. Among patients with RRHL, >80% received first salvage chemotherapy. The most common first salvage regimens were etoposide, methylprednisolone, cytarabine, and cisplatin in Saudi Arabia (78.3%) and dexamethasone, cytarabine, and cisplatin in Türkiye (36.1%) and South Africa (40%). Median PFS (95% confidence interval [CI]) in the RRHL group was 5.1 (3.0-15.9), 19.7 (7.5-not reached), and 5.2 (1.1-10.1) months in Saudi Arabia, Türkiye, and South Africa, respectively. The 5-year PFS and overall survival (95% CI) rates in patients with RRHL were 33.2% (21.6-45.2) and 78.2% (65.9-86.5) in Saudi Arabia, 42.5% (29.5-54.9) and 79.4% (67.2-87.5) in Türkiye, and 13.1% (4.2-27.0) and 53% (35.5-67.8) in South Africa, respectively.

Conclusion: This study showed that the clinical outcomes in Türkiye and Saudi Arabia were generally comparable with those of Western countries during the study period, although Saudi Arabia had lower PFS rates. Conversely, the clinical outcomes in South Africa were suboptimal, emphasizing the need for novel therapies and improved progression to stem cell transplantation. These data may serve as a control group for future studies in these countries and inform clinical decision-making.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

沙特阿拉伯、土耳其和南非霍奇金淋巴瘤患者的治疗模式和临床结果：国际多中心回顾性 BHOLISTIC 研究的分组分析。

研究目的B-HOLISTIC是一项关于欧洲和北美以外地区霍奇金淋巴瘤（HL）治疗模式和临床结果的真实世界回顾性研究。本亚组分析报告了沙特阿拉伯、土耳其和南非的研究结果：对 2010 年 1 月至 2013 年 12 月期间年龄≥18 岁、诊断为 IIB-IV 期典型 HL 并接受一线化疗（一线 cHL）和/或复发/难治性 HL（RRHL）的患者进行了评估。主要终点是RRHL患者的无进展生存期（PFS）：共有 694 例患者（RRHL：178 例；一线 cHL：653 例）入组。在RRHL患者中，超过80%的患者接受了首次挽救性化疗。在沙特阿拉伯，最常见的首次挽救方案是依托泊苷、甲基强的松龙、阿糖胞苷、顺铂（ESHAP）（78.3%）；在土耳其（36.1%）和南非（40%），最常见的首次挽救方案是地塞米松、阿糖胞苷、顺铂（DHAP）。沙特阿拉伯、土耳其和南非 RRHL 组的中位生存期（95% 置信区间 [CI]）分别为 5.1 个月（3.0-15.9）、19.7 个月（7.5-未达到）和 5.2 个月（1.1-10.1）。RRHL患者的5年PFS和总生存率（95% CI）在沙特阿拉伯分别为33.2%（21.6-45.2）和78.2%（65.9-86.5），在土耳其分别为42.5%（29.5-54.9）和79.4%（67.2-87.5），在南非分别为13.1%（4.2-27.0）和53%（35.5-67.8）：本研究表明，在研究期间，土耳其和沙特阿拉伯的临床结果与西方国家基本相当，但沙特阿拉伯的 PFS 率较低。相反，南非的临床疗效并不理想，强调了新型疗法和改善干细胞移植进展的必要性。此外，这些数据可作为这些国家未来研究的对照组，为临床决策提供参考。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Turkish Journal of Hematology HEMATOLOGY-

CiteScore

2.90

自引率

3.80%

发文量

审稿时长

1 months

期刊介绍： The Turkish Journal of Hematology is published quarterly (March, June, September, and December) by the Turkish Society of Hematology. It is an independent, non-profit peer-reviewed international English-language periodical encompassing subjects relevant to hematology. The Editorial Board of The Turkish Journal of Hematology adheres to the principles of the World Association of Medical Editors (WAME), International Council of Medical Journal Editors (ICMJE), Committee on Publication Ethics (COPE), Consolidated Standards of Reporting Trials (CONSORT) and Strengthening the Reporting of Observational Studies in Epidemiology (STROBE). The aim of The Turkish Journal of Hematology is to publish original hematological research of the highest scientific quality and clinical relevance. Additionally, educational material, reviews on basic developments, editorial short notes, images in hematology, and letters from hematology specialists and clinicians covering their experience and comments on hematology and related medical fields as well as social subjects are published. As of December 2015, The Turkish Journal of Hematology does not accept case reports. Important new findings or data about interesting hematological cases may be submitted as a brief report.